Most Read Articles
Audrey Abella, 09 Jun 2017
Maintenance therapy with olaparib significantly improved progression-free survival (PFS) and patient-centred benefits in patients with germline BRCA-mutated, platinum-sensitive relapsed serous ovarian cancer (gBRCAm PSR SOC) compared with placebo, according to the SOLO* 2 trial presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2017 held in Chicago, Illinois, US.
Elvira Manzano, 14 Jun 2017
The oral PARP inhibitor olaparib significantly improved progression-free survival (PFS) in women with BRCA-positive, HER2-negative breast cancer compared with standard chemotherapy in the phase III OlympiAD* trial, ushering in a new era of hope in BRCA-mutated breast cancer.
Pearl Toh, 01 Aug 2016
Understanding biomarkers predictive of treatment outcomes or response can help inform treatment decisions and personalize care for advanced prostate cancer patients, suggested an expert at the recent Urological Association of Asia Annual Congress (UAA 2016) held in Singapore.
Audrey Abella, 13 Jun 2017
A psychological intervention, Conquer Fear, may help alleviate fear of cancer recurrence (FCR) in cancer survivors, according to a study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2017 held in Chicago, Illinois, US.

Blood type tied to prognosis in hepatocellular carcinoma

13 Jul 2017

Blood type is associated with prognosis in Chinese hepatocellular carcinoma (HCC) patients, a new study reveals. Those with non-O blood types particularly have poorer overall survival (OS).

Over a median follow-up of 36 (25 to 75) months, 392 of the 691 HCC patients who received hepatectomy died. The 3- and 5-year survival rates were 52.9 and 38.7 percent, respectively.

Blood group was significantly associated with OS (p=0.001). The median OS for blood type O was 55 (95 percent CI, 42.69 to 67.31) months, type A 39 (32.20 to 45.80) months, type B 34 (26.58 to 41.42) months and type AB 34 (24.09 to 43.91) months.

Because the 1-, 3- and 5-year OS values for the blood type O group (88.2, 58.8 and 47.3 percent, respectively) were significantly higher than the type A/B/AB groups, which had comparable OS values (p=0.226), the study cohort was divided into O vs non-O blood type groups.

The resulting median OS for the blood type O group was 55 (42.69 to 67.30) months vs 36 (31.18 to 40.81) months for the non-O blood type group. Patients with blood type O had significantly better survival than those with non-O blood types (1-year OS, 88.2 vs 83.4 percent; 3-year OS, 58.5 vs 49.1 percent; 5-year OS, 47.3 vs 30.5 percent; p<0.001 for all).

Multivariate Cox regression analysis revealed that blood types A (hazard ratio [HR], 1.416; 95 percent CI, 1.101 to 1.820; p=0.007), B (HR, 1.736; 1.333 to 2.262; p<0.001) and AB (HR, 1.739; 1.210 to 2.499; p=0.006) were significant poor prognostic factors for HCC following hepatectomy.

The non-O blood type group (HR, 1.485; 1.204 to 1.830; p<0.001) had significantly worse OS compared with the O blood type group.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Audrey Abella, 09 Jun 2017
Maintenance therapy with olaparib significantly improved progression-free survival (PFS) and patient-centred benefits in patients with germline BRCA-mutated, platinum-sensitive relapsed serous ovarian cancer (gBRCAm PSR SOC) compared with placebo, according to the SOLO* 2 trial presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2017 held in Chicago, Illinois, US.
Elvira Manzano, 14 Jun 2017
The oral PARP inhibitor olaparib significantly improved progression-free survival (PFS) in women with BRCA-positive, HER2-negative breast cancer compared with standard chemotherapy in the phase III OlympiAD* trial, ushering in a new era of hope in BRCA-mutated breast cancer.
Pearl Toh, 01 Aug 2016
Understanding biomarkers predictive of treatment outcomes or response can help inform treatment decisions and personalize care for advanced prostate cancer patients, suggested an expert at the recent Urological Association of Asia Annual Congress (UAA 2016) held in Singapore.
Audrey Abella, 13 Jun 2017
A psychological intervention, Conquer Fear, may help alleviate fear of cancer recurrence (FCR) in cancer survivors, according to a study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2017 held in Chicago, Illinois, US.